U.S. markets open in 3 hours 8 minutes
  • S&P Futures

    3,860.50
    +41.25 (+1.08%)
     
  • Dow Futures

    31,964.00
    +188.00 (+0.59%)
     
  • Nasdaq Futures

    12,570.75
    +273.50 (+2.22%)
     
  • Russell 2000 Futures

    2,236.60
    +35.80 (+1.63%)
     
  • Crude Oil

    65.83
    +0.78 (+1.20%)
     
  • Gold

    1,702.80
    +24.80 (+1.48%)
     
  • Silver

    25.82
    +0.55 (+2.16%)
     
  • EUR/USD

    1.1915
    +0.0062 (+0.52%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.51
    -0.15 (-0.61%)
     
  • GBP/USD

    1.3882
    +0.0060 (+0.43%)
     
  • USD/JPY

    108.6820
    -0.2190 (-0.20%)
     
  • BTC-USD

    54,184.20
    +4,103.77 (+8.19%)
     
  • CMC Crypto 200

    1,093.84
    +69.63 (+6.80%)
     
  • FTSE 100

    6,760.86
    +41.73 (+0.62%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

An Intrinsic Calculation For Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Suggests It's 50% Undervalued

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·6 min read
  • Oops!
    Something went wrong.
    Please try again later.

Today we will run through one way of estimating the intrinsic value of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by taking the forecast future cash flows of the company and discounting them back to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

Check out our latest analysis for Reata Pharmaceuticals

Is Reata Pharmaceuticals fairly valued?

We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

10-year free cash flow (FCF) forecast

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

-US$284.4m

-US$296.8m

-US$216.1m

US$179.6m

US$256.6m

US$335.1m

US$408.9m

US$474.4m

US$530.6m

US$577.8m

Growth Rate Estimate Source

Analyst x1

Analyst x1

Analyst x1

Analyst x1

Est @ 42.84%

Est @ 30.6%

Est @ 22.03%

Est @ 16.03%

Est @ 11.84%

Est @ 8.9%

Present Value ($, Millions) Discounted @ 6.2%

-US$268

-US$263

-US$180

US$141

US$190

US$233

US$268

US$293

US$308

US$316

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$1.0b

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.2%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$578m× (1 + 2.0%) ÷ (6.2%– 2.0%) = US$14b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$14b÷ ( 1 + 6.2%)10= US$7.7b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$8.7b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of US$122, the company appears quite undervalued at a 50% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

Important assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Reata Pharmaceuticals as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.2%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Can we work out why the company is trading at a discount to intrinsic value? For Reata Pharmaceuticals, we've put together three further items you should consider:

  1. Risks: Every company has them, and we've spotted 3 warning signs for Reata Pharmaceuticals you should know about.

  2. Future Earnings: How does RETA's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.